RiteDose manufacturing adjustments expected to generate up to 25% increase in production capacity

The RiteDose Corporation, a pharma company that specializes in blow-fill-seal (BFS) manufacturing and outsourcing solutions, has applied engineering changes that the contract development and manufacturing organization (CDMO) says will allow it to increase production capacity by up to 25% over industry standards.

These aforementioned modifications applied to RiteDose’s production lines in Columbia, SC will help the company tackle surge demands and bring faster time-to-market efficiencies for pharma companies developing new product lines.

“Our engineers have made significant changes in our production methodology and processes that will allow us to increase production capacity by up to 200 million units per year—substantially beyond standard industry outputs,” says Jody Chastain, RiteDose CEO. “This latest innovation pushes our BFS capacity to more than 2 billion units annually.”

The improvements are part of a $20 million capital avoidance strategy that the company has implemented to create flexibility in its production capacity and capability.